Chapter 11. Liver Disease in Obesity

  1. Gareth Williams3 and
  2. Gema Frühbeck4
  1. Nimantha de Alwis1 and
  2. Chris Day2

Published Online: 28 APR 2009

DOI: 10.1002/9780470712221.ch11

Obesity: Science to Practice

Obesity: Science to Practice

How to Cite

Alwis, N. d. and Day, C. (2009) Liver Disease in Obesity, in Obesity: Science to Practice (eds G. Williams and G. Frühbeck), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470712221.ch11

Editor Information

  1. 3

    Faculty of Medicine and Dentistry, University of Bristol, Bristol, UK

  2. 4

    Department of Endocrinology, Clínica Universitaria, de Navarra, Avda. Pío XII, 36, 31008 - Pamplona, Spain

Author Information

  1. 1

    Faculty of Medical Sciences Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK

  2. 2

    Clinical Medical Sciences, 4th Floor William Leech Building, Medical School, Framlington Place, University of Newcastle upon Tyne, NE2 4HH, UK

Publication History

  1. Published Online: 28 APR 2009
  2. Published Print: 27 MAR 2009

ISBN Information

Print ISBN: 9780470019115

Online ISBN: 9780470712221



  • liver disease in obesity;
  • non–alcoholic fatty liver disease (NAFLD);
  • hepatocellular carcinoma (HCC);
  • microsomal transfer protein (MTP);
  • phosphatidyl e-methyl transferase (PEMT);
  • hepatocyte damage – enhanced by oxidative stress free radical generation;
  • hepatic fibrosis in NAFLD – due partly to the general response to inflammation and hepatocyte injury;
  • pharmacological anti-obesity agents;
  • ursodeoxycholic acid (UDCA)


This chapter contains sections titled:

  • Epidemiology

  • Pathogenesis of NAFLD in obesity

  • Pathology of NAFLD

  • Natural history of NAFLD

  • Clinical presentation

  • Investigation of suspected NAFLD

  • Management of patients with NAFLD

  • References